EUVIMEDEUVIMED entdecken
Crossref

Role of abetimus in systemic lupus erythematosus

Manuja Joshi, Michael P Madaio

Future Rheumatology · 2006

DOI: 10.2217/17460816.1.2.167 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Rheumatology, 2006. Verfasst von Manuja Joshi und 1 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti-DNA antibodies and the B cells that produce them play a major pathogenic role in lupus nephritis. Although current immunosuppressive therapy suppresses autoantibody production and B-cell activity, it is often associated with severe side effects. Abetimus, a soluble, synthetic, double-stranded (ds)DNA tetramer, was developed to bind to circulating DNA antibodies and membrane-bound anti-DNA antibodies on B cells, with the goal of removing circulating pathogenic antibodies and inducing B-cell tolerance. Two large clinical trials with this agent have shown promising results in reducing lupus nephritis flares, especially in patients with high affinity anti-dsDNA antibodies. Nevertheless, although safe and well tolerated, the second trial did not reproduce the desired, statistically significant end point. This was probably due to the trial design and, therefore, given its potential efficacy and safety profile, it seems that once dosing is optimized and the responsive patient population is defined, abetimus...

Zitieren

APA

Joshi, M., & Madaio, M. P. (2006). Role of abetimus in systemic lupus erythematosus. Future Rheumatology. https://doi.org/10.2217/17460816.1.2.167

Vancouver

Joshi M, Madaio MP. Role of abetimus in systemic lupus erythematosus. Future Rheumatology. 2006. doi:10.2217/17460816.1.2.167

BibTeX
@article{Joshi2006,
  author = {Joshi, Manuja and Madaio, Michael P},
  title = {Role of abetimus in systemic lupus erythematosus},
  journal = {Future Rheumatology},
  year = {2006},
  doi = {10.2217/17460816.1.2.167}
}
Kostenlos starten →